ROVI announces its financial results for the full year 2025, an inflection point in which took strategic steps forward to reinforce its international reach and ensure the company’s long-term creation of sustainable value.
- Acquisition of a manufacturing facility for injectable pharmaceuticals in Phoenix, Arizona (USA) to Bristol Myers Squibb and a Toll Manufacturing Agreement, which regulates the conditions under which ROIS Phoenix Inc. will continue to manufacture for BMS at the facility.
- ROVI will also collaborate with Roche for the manufacture of a new medicine, currently in the clinical development phase, from it’s metabolic and cardiovascular portfolio.
Total revenue in 2025 was 756.1 million euros, a 1% decrease on 2024. ROVI booked operating revenue of 743.5 million euros, representing a 3% decrease on 2024, due to the behaviour of the contract development and manufacturing business (CDMO).
In addition, the contract manufacturing business (CDMO) booked sales of 269.5 million euros.
Notwithstanding, sales of the specialty pharmaceutical business rose 11% to 473.9 million euros this year.
Risperidone ISM® continues its strong growth reaching total sales of 56.7 million euros. This represents a 97% increase over sales registered on 2024.
Sales of the heparin franchise, which includes low-molecular-weight heparins and other heparins, increased 7% to 266.8 million euros, due to the increase in orders from international partners. The main contributor to the division’s growth was enoxaparin, sales of which rose 9% to 157.7 million euros as a result of an increase in orders from partners during 2025. Bemiparin sales increased by 4% in 2025 in comparison to 2024.
Gross profit increased 3% to 494.7 million euros in 2025, reflecting an increase of the gross margin of 3.9 percentage points to 66.5% in 2025.
Likewise, in 2025 EBITDA increased to 216.2 million euros, reflecting a 1.9 percentage point rise in the EBITDA margin, which reached 29.1% in 2025.
Net profit rose 3% to 140.4million euros..
For 2026, ROVI expects operating revenue to increase by between a high single-digit and low double-digit percentage.